NA
FLNA

NewEdge Advisors’s Filana Therapeutics FLNA Stock Holding History

NewEdge Advisors’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.7K Buy
28,300
+25,000
+758% +$35.6K ﹤0.01% 3217
2026
Q1 		$5.58K Sell
3,300
-725
-18% -$1.49K ﹤0.01% 3561
2025
Q4 		$7.97K Sell
4,025
-300
-7% -$960 ﹤0.01% 3533
2025
Q3 		$12.6K Hold
4,325
– – ﹤0.01% 3262
2025
Q2 		$7.83K Hold
4,325
– – ﹤0.01% 3277
2025
Q1 		$6.49K Buy
4,325
+1,750
+68% +$4.42K ﹤0.01% 3226
2024
Q4 		$6.08K Buy
2,575
+2,075
+415% +$36.4K ﹤0.01% 3177
2024
Q3 		$14.7K Hold
500
– – ﹤0.01% 2822
2024
Q2 		$6.18K Buy
500
+300
+150% +$6.32K ﹤0.01% 3021
2024
Q1 		$4.06K Buy
200
+150
+300% +$3.46K ﹤0.01% 3206
2023
Q4 		$1.13K Hold
50
– – ﹤0.01% 3446
2023
Q3 		$832 Hold
50
– – ﹤0.01% 3195
2023
Q2 		$1.23K Sell
50
-400
-89% -$9.63K ﹤0.01% 3209
2023
Q1 		$10.9K Hold
450
– – ﹤0.01% 2540
2022
Q4 		$13 Buy
+450
New +$16.2K ﹤0.01% 3671

Other funds holding FLNA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

NewEdge Advisors's FLNA Position: Q2 2026 in Review

NewEdge Advisors increased its Filana Therapeutics (FLNA) stake by 758% in Q2 2026, buying an estimated $35.6K and bringing the position to 28,300 shares worth $33.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3217.

NewEdge Advisors first reported a position in FLNA in Q4 2022 and has held it in 15 quarters since. 84 funds tracked by Wall St. Rank hold FLNA as of Q2 2026.

  • NewEdge Advisors held 28,300 shares of Filana Therapeutics worth $33.7K as of Q2 2026.
  • NewEdge Advisors bought 25,000 Filana Therapeutics shares in Q2 2026, an estimated $35.6K.
  • Filana Therapeutics made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3217 holding.
  • NewEdge Advisors first reported a position in Filana Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • 84 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.